Medicare, Medicaid, and Children's Health Insurance Programs; Provider Enrollment Application Fee Amount for Calendar Year 2024, 76754-76756 [2023-24607]
Download as PDF
khammond on DSKJM1Z7X2PROD with NOTICES
76754
Federal Register / Vol. 88, No. 214 / Tuesday, November 7, 2023 / Notices
Applicants: Tennessee Gas Pipeline
Company, L.L.C.
Description: Compliance filing: CostRevenue Study Docket No. RP19–
351__to be effective N/A.
Filed Date: 11/1/23.
Accession Number: 20231101–5073.
Comment Date: 5 p.m. ET 11/13/23.
Docket Numbers: RP23–1038–000.
Applicants: Transcontinental Gas
Pipe Line Company, LLC.
Description: Report Filing: In-Service
Notice_REA Interim_a_Docket No.
CP21–94 to be effective N/A.
Filed Date: 10/31/23.
Accession Number: 20231031–5157.
Comment Date: 5 p.m. ET 11/13/23.
Docket Numbers: RP23–1055–000.
Applicants: Transcontinental Gas
Pipe Line Company, LLC.
Description: Report Filing: In-Service
Notice_REA Interim_b_Docket No.
CP21–94 to be effective N/A.
Filed Date: 10/31/23.
Accession Number: 20231031–5164.
Comment Date: 5 p.m. ET 11/13/23.
Any person desiring to protest in any
the above proceedings must file in
accordance with Rule 211 of the
Commission’s Regulations (18 CFR
385.211) on or before 5:00 p.m. Eastern
time on the specified comment date.
The filings are accessible in the
Commission’s eLibrary system (https://
elibrary.ferc.gov/idmws/search/
fercgensearch.asp) by querying the
docket number.
eFiling is encouraged. More detailed
information relating to filing
requirements, interventions, protests,
service, and qualifying facilities filings
can be found at: https://www.ferc.gov/
docs-filing/efiling/filing-req.pdf. For
other information, call (866) 208–3676
(toll free). For TTY, call (202) 502–8659.
The Commission’s Office of Public
Participation (OPP) supports meaningful
public engagement and participation in
Commission proceedings. OPP can help
members of the public, including
landowners, environmental justice
communities, Tribal members and
others, access publicly available
information and navigate Commission
processes. For public inquiries and
assistance with making filings such as
interventions, comments, or requests for
rehearing, the public is encouraged to
contact OPP at (202) 502–6595 or OPP@
ferc.gov.
Dated: November 1, 2023.
Debbie-Anne A. Reese,
Deputy Secretary.
[FR Doc. 2023–24590 Filed 11–6–23; 8:45 am]
BILLING CODE 6717–01–P
VerDate Sep<11>2014
16:30 Nov 06, 2023
Jkt 262001
DEPARTMENT OF ENERGY
Federal Energy Regulatory
Commission
[Project No. 7883–020]
Powerhouse Systems, Inc.; Notice of
Technical Conference
On Wednesday, November 15, 2023,
Commission staff will hold a technical
conference to provide clarification to
Powerhouse Systems, Inc (Powerhouse)
regarding the Exhibit F Supporting
Design Report (SDR), for the Weston
Dam Hydroelectric Project No. 7883.
The conference will be held via
teleconference beginning at 10:30 a.m.
eastern standard time. Discussion topics
for the technical conference include: (1)
the information provided in the
Powerhouse’s Exhibit F SDR filed on
October 2, 2023; and (2) information
required to provide an updated SDR that
meets Commission regulations.
All local, State, and Federal agencies,
Indian Tribes, and other interested
parties are invited to participate. There
will be no transcript of the conference,
but a summary of the meeting will be
prepared for the project record. If you
are interested in participating in the
meeting you must contact John
Baummer at (202) 502–6837 or
john.baummer@ferc.gov by November
10, 2023 to receive specific instructions
on how to participate.
Dated: November 1, 2023.
Debbie-Anne A. Reese,
Deputy Secretary.
contacting the appropriate Federal
Reserve Bank and from the Board’s
Freedom of Information Office at
https://www.federalreserve.gov/foia/
request.htm. Interested persons may
express their views in writing on the
standards enumerated in paragraph 7 of
the Act.
Comments regarding each of these
applications must be received at the
Reserve Bank indicated or the offices of
the Board of Governors, Ann E.
Misback, Secretary of the Board, 20th
Street and Constitution Avenue NW,
Washington, DC 20551–0001, not later
than November 22, 2023.
A. Federal Reserve Bank of Kansas
City (Jeffrey Imgarten, Assistant Vice
President) One Memorial Drive, Kansas
City, Missouri, 64198. Comments can
also be sent electronically to
KCapplicationcomments@kc.frb.org:
1. Sarah George, Louisburg, Kansas; to
join the Shannon Family Control Group,
a group acting in concert, to acquire
voting shares of Central Kansas
Bancshares, Inc., Woodbine, Kansas,
and thereby indirectly acquire voting
shares of The Citizens State Bank and
Trust Company, Council Grove, Kansas.
Board of Governors of the Federal Reserve
System.
Michele Taylor Fennell,
Deputy Associate Secretary of the Board.
[FR Doc. 2023–24571 Filed 11–6–23; 8:45 am]
BILLING CODE P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2023–24589 Filed 11–6–23; 8:45 am]
BILLING CODE 6717–01–P
Centers for Medicare & Medicaid
Services
[CMS–6093–N]
FEDERAL RESERVE SYSTEM
RIN 0938–ZB79
Change in Bank Control Notices;
Acquisitions of Shares of a Bank or
Bank Holding Company
Medicare, Medicaid, and Children’s
Health Insurance Programs; Provider
Enrollment Application Fee Amount for
Calendar Year 2024
The notificants listed below have
applied under the Change in Bank
Control Act (Act) (12 U.S.C. 1817(j)) and
§ 225.41 of the Board’s Regulation Y (12
CFR 225.41) to acquire shares of a bank
or bank holding company. The factors
that are considered in acting on the
applications are set forth in paragraph 7
of the Act (12 U.S.C. 1817(j)(7)).
The public portions of the
applications listed below, as well as
other related filings required by the
Board, if any, are available for
immediate inspection at the Federal
Reserve Bank(s) indicated below and at
the offices of the Board of Governors.
This information may also be obtained
on an expedited basis, upon request, by
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
Centers for Medicare &
Medicaid Services (CMS), HHS.
ACTION: Notice.
AGENCY:
This notice announces a
$709.00 calendar year (CY) 2024
application fee for institutional
providers that are initially enrolling in
the Medicare or Medicaid program or
the Children’s Health Insurance
Program (CHIP); revalidating their
Medicare, Medicaid, or CHIP
enrollment; or adding a new Medicare
practice location. This fee is required
with any enrollment application
submitted on or after January 1, 2024
and on or before December 31, 2024.
SUMMARY:
E:\FR\FM\07NON1.SGM
07NON1
Federal Register / Vol. 88, No. 214 / Tuesday, November 7, 2023 / Notices
The application fee announced
in this notice is effective on January 1,
2024.
FOR FURTHER INFORMATION CONTACT:
Frank Whelan, (410) 786–1302.
SUPPLEMENTARY INFORMATION:
khammond on DSKJM1Z7X2PROD with NOTICES
DATES:
I. Background
In the February 2, 2011 Federal
Register (76 FR 5862), we published a
final rule with comment period titled
‘‘Medicare, Medicaid, and Children’s
Health Insurance Programs; Additional
Screening Requirements, Application
Fees, Temporary Enrollment Moratoria,
Payment Suspensions and Compliance
Plans for Providers and Suppliers.’’ This
rule finalized, among other things,
provisions related to the submission of
application fees as part of the Medicare,
Medicaid, and CHIP provider
enrollment processes. As provided in
section 1866(j)(2)(C)(i) of the Social
Security Act (the Act) and in 42 CFR
424.514, ‘‘institutional providers’’ that
are initially enrolling in the Medicare or
Medicaid programs or CHIP,
revalidating their enrollment, or adding
a new Medicare practice location are
required to submit a fee with their
enrollment application. An
‘‘institutional provider’’ for purposes of
Medicare is defined at § 424.502 as ‘‘any
provider or supplier that submits a
paper Medicare enrollment application
using the CMS–855A, CMS–855B (not
including physician and non-physician
practitioner organizations), CMS–855S,
or associated internet-based PECOS
enrollment application.’’ As we
explained in the February 2, 2011 final
rule (76 FR 5914), in addition to the
providers and suppliers subject to the
application fee under Medicare,
Medicaid-only and CHIP-only
institutional providers would include
nursing facilities, intermediate care
facilities for persons with intellectual
disabilities (ICF/IID), and psychiatric
residential treatment facilities; they may
also include other institutional provider
types designated by a state in
accordance with their approved state
plan.
As indicated in § 424.514 and
§ 455.460, the application fee is not
required for either of the following:
• A Medicare physician or nonphysician practitioner submitting a
CMS–855I.
• A prospective or revalidating
Medicaid or CHIP provider—
++ Who is an individual physician or
non-physician practitioner; or
++ That is enrolled as an institutional
provider in Title XVIII of the Act or
another state’s Title XIX or XXI plan
and has paid the application fee to a
Medicare contractor or another state.
VerDate Sep<11>2014
16:30 Nov 06, 2023
Jkt 262001
II. Provisions of the Notice
Section 1866(j)(2)(C)(i)(I) of the Act
established a $500 application fee for
institutional providers in CY 2010.
Consistent with section
1866(j)(2)(C)(i)(II) of the Act,
§ 424.514(d)(2) states that for CY 2011
and subsequent years, the preceding
year’s fee will be adjusted by the
percentage change in the consumer
price index (CPI) for all urban
consumers (all items; United States city
average, CPI–U) for the 12-month period
ending on June 30 of the previous year.
Consequently, each year since 2011 we
have published in the Federal Register
an announcement of the application fee
amount for the forthcoming CY based on
this formula. Most recently, in the
December 5, 2022 Federal Register (87
FR 74422), we published a notice
announcing a fee amount for the period
of January 1, 2023 through December 31,
2023 of $688.00. The $688.00 fee
amount for CY 2023 will be used to
calculate the fee amount for 2024 as
specified in § 424.514(d)(2).
According to Bureau of Labor
Statistics (BLS) data, the CPI–U increase
for the period of July 1, 2022 through
June 30, 2023 was 3.0 percent. As
required by § 424.514(d)(2), the
preceding year’s fee of $688 will be
adjusted by 3.0 percent. This results in
a CY 2024 application fee amount of
$708.64 ($688 x 1.03). As we must
round this to the nearest whole dollar
amount, the resultant application fee
amount for CY 2024 is $709.00.
III. Collection of Information
Requirements
This document does not impose
information collection requirements
(that is, reporting, recordkeeping, or
third-party disclosure requirements).
Accordingly, there is no need for review
by the Office of Management and
Budget under the authority of the
Paperwork Reduction Act of 1995.
However, it does reference previously
approved information collections. The
CMS–855A, CMS–855B, CMS–855I, and
CMS–855S applications are approved
under, respectively, OMB control
numbers 0938–0685, 0938–1377, 0938–
1355, and 0938–1056.
IV. Regulatory Impact Statement
A. Background and Review
Requirements
We have examined the impact of this
notice as required by Executive Order
12866 on Regulatory Planning and
Review (September 30, 1993), Executive
Order 13563 on Improving Regulation
and Regulatory Review (January 18,
2011), the Regulatory Flexibility Act
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
76755
(RFA) (September 19, 1980, Pub. L. 96–
354), section 1102(b) of the Act, section
202 of the Unfunded Mandates Reform
Act of 1995 (March 22, 1995; Pub. L.
104–4), and Executive Order 13132 on
Federalism (August 4, 1999).
Executive Orders 12866 and 13563
direct agencies to assess all costs and
benefits of available regulatory
alternatives and, if regulation is
necessary, to select regulatory
approaches that maximize net benefits
(including potential economic,
environmental, public health and safety
effects, distributive impacts, and
equity). The Executive Order 14094
entitled ‘‘Modernizing Regulatory
Review’’ (hereinafter, the Modernizing
E.O.) amends section 3(f)(1) of Executive
Order 12866 (Regulatory Planning and
Review). The amended section 3(f) of
Executive Order 12866 defines a
‘‘significant regulatory action’’ as an
action that is likely to result in a rule:
(1) having an annual effect on the
economy of $200 million or more in any
1 year (adjusted every 3 years by the
Administrator of OIRA for changes in
gross domestic product), or adversely
affect in a material way the economy, a
sector of the economy, productivity,
competition, jobs, the environment,
public health or safety, or State, local,
territorial, or tribal governments or
communities; (2) creating a serious
inconsistency or otherwise interfering
with an action taken or planned by
another agency; (3) materially altering
the budgetary impacts of entitlement
grants, user fees, or loan programs or the
rights and obligations of recipients
thereof; or (4) raise legal or policy issues
for which centralized review would
meaningfully further the President’s
priorities or the principles set forth in
this Executive order, as specifically
authorized in a timely manner by the
Administrator of OIRA in each case.
A regulatory impact analysis (RIA)
must be prepared for major rules with
significant regulatory action/s and/or
with significant effects as per section
3(f)(1) ($200 million or more in any 1
year). Accordingly, we have prepared a
Regulatory Impact Analysis that to the
best of our ability presents the costs and
benefits of the rulemaking. Based on our
estimates, OMB’s Office of Information
and Regulatory Affairs has determined
that this notice is ‘‘not significant’’ and
‘‘not major’’.
B. Costs
The costs associated with this notice
involve the increase in the application
fee amount that certain providers and
suppliers must pay in CY 2024. The CY
2024 cost estimates are as follows:
E:\FR\FM\07NON1.SGM
07NON1
76756
Federal Register / Vol. 88, No. 214 / Tuesday, November 7, 2023 / Notices
1. Medicare
Based on CMS data, we estimate that
in CY 2024 approximately—
• 14,232 newly enrolling institutional
providers will be subject to and pay an
application fee; and
• 36,142 revalidating institutional
providers will be subject to and pay an
application fee.
Using a figure of 50,374 (14,232 newly
enrolling + 36,142 revalidating)
institutional providers, we estimate an
increase in the cost of the Medicare
application fee requirement in CY 2024
of $1,057,854 (or 50,374 x $21 (or $709
minus $688)) from our CY 2023
projections.
2. Medicaid and CHIP
Based on CMS and state statistics, we
estimate that approximately 30,000
(9,000 newly enrolling + 21,000
revalidating) Medicaid and CHIP
institutional providers will be subject to
an application fee in CY 2024. Using
this figure, we project an increase in the
cost of the Medicaid and CHIP
application fee requirement in CY 2024
of $630,000 (or 30,000 × $21 (or $709
minus $688)) from our CY 2023
projections.
khammond on DSKJM1Z7X2PROD with NOTICES
3. Total
Based on the foregoing, we estimate
the total increase in the cost of the
application fee requirement for
Medicare, Medicaid, and CHIP
providers and suppliers in CY 2024 to
be $1,687,854 ($1,057,854 + $630,000)
from our CY 2023 projections.
We do not anticipate any negative
impact on equity from the increase in
the application fee amount, which we
calculated in accordance with the
requirements specified in statute and
regulation. Prior application fee
increases have had no such discernable
effect, and we reiterate that the fee
requirement does not apply to
individual physicians and nonphysician practitioners completing the
CMS–855I, who represent the
overwhelming preponderance of the
more than 2 million Medicare-enrolled
providers and suppliers.
The RFA requires agencies to analyze
options for regulatory relief of small
businesses. For purposes of the RFA,
small entities include small businesses,
nonprofit organizations, and small
governmental jurisdictions. Most
hospitals and most other providers and
suppliers are small entities, either by
nonprofit status or by having revenues
of less than $9 million to $47 million in
any 1 year. Individuals and states are
not included in the definition of a small
entity. As we stated in the RIA for the
VerDate Sep<11>2014
16:30 Nov 06, 2023
Jkt 262001
February 2, 2011 final rule (76 FR 5952),
we do not believe that the application
fee will have a significant impact on
small entities.
In addition, section 1102(b) of the Act
requires us to prepare a regulatory
impact analysis if a rule may have a
significant impact on the operations of
a substantial number of small rural
hospitals. This analysis must conform to
the provisions of section 604 of the
RFA. For purposes of section 1102(b) of
the Act, we define a small rural hospital
as a hospital that is located outside of
a Metropolitan Statistical Area for
Medicare payment regulations and has
fewer than 100 beds. We are not
preparing an analysis for section 1102(b)
of the Act because we have determined,
and the Secretary certifies, that this
notice would not have a significant
impact on the operations of a substantial
number of small rural hospitals.
Section 202 of the Unfunded
Mandates Reform Act of 1995 (UMRA)
also requires that agencies assess
anticipated costs and benefits before
issuing any rule whose mandates
require spending in any 1 year of $100
million in 1995 dollars, updated
annually for inflation. In 2023, that
threshold was approximately
$198million. The Agency has
determined that there will be minimal
impact from the costs of this notice, as
the threshold is not met under the
UMRA.
Executive Order 13132 establishes
certain requirements that an agency
must meet when it promulgates a
proposed rule (and subsequent final
rule) that imposes substantial direct
requirement costs on state and local
governments, preempts state law, or
otherwise has federalism implications.
Since this notice does not impose
substantial direct costs on state or local
governments, the requirements of
Executive Order 13132 are not
applicable.
In accordance with the provisions of
Executive Order 12866, this notice was
reviewed by the Office of Management
and Budget.
The Administrator of the Centers for
Medicare & Medicaid Services (CMS),
Chiquita Brooks-LaSure, having
reviewed and approved this document,
authorizes Chyana Woodyard, who is
the Federal Register Liaison, to
electronically sign this document for
purposes of publication in the Federal
Register.
Chyana Woodyard,
Federal Register Liaison, Centers for Medicare
& Medicaid Services.
[FR Doc. 2023–24607 Filed 11–6–23; 8:45 am]
BILLING CODE 4120–01–P
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2023–N–4742]
Phibro Animal Health Corp.; Proposal
To Withdraw Approval of New Animal
Drug Applications for Carbadox in
Medicated Swine Feed; Opportunity for
a Hearing
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or the Agency),
Center for Veterinary Medicine (CVM),
is proposing to withdraw approval of all
new animal drug applications (NADAs)
providing for use of carbadox in
medicated swine feed, for which Phibro
Animal Health Corp., Glenpointe Centre
East, Third Floor, 300 Frank W. Burr
Blvd., Suite 21, Teaneck, NJ 07666–
6712, is the sponsor, and is announcing
an opportunity for the holder of the
NADAs to request a hearing on this
proposal. This action is based on CVM’s
determination that there is no approved
regulatory method to detect the residue
of carcinogenic concern in the edible
tissues of the treated swine.
DATES: The sponsor of the NADAs may
submit a written request for a hearing by
December 7, 2023. Submit all data,
information, and analyses upon which a
request for a hearing relies by December
7, 2023. Either electronic or written
comments on the notice must be
submitted by December 7, 2023.
ADDRESSES: The request for a hearing
may be submitted by the sponsor of the
NADAs by either of the following
methods:
SUMMARY:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments to
submit your request for hearing. Your
request for a hearing submitted
electronically, including any
attachments to the request for hearing,
to https://www.regulations.gov will be
posted to the docket unchanged.
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand Delivery/Courier (for
written/paper request for a hearing):
Dockets Management Staff (HFA–305),
Food and Drug Administration, 5630
Fishers Lane, Rm. 1061, Rockville, MD
20852.
E:\FR\FM\07NON1.SGM
07NON1
Agencies
[Federal Register Volume 88, Number 214 (Tuesday, November 7, 2023)]
[Notices]
[Pages 76754-76756]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-24607]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
[CMS-6093-N]
RIN 0938-ZB79
Medicare, Medicaid, and Children's Health Insurance Programs;
Provider Enrollment Application Fee Amount for Calendar Year 2024
AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This notice announces a $709.00 calendar year (CY) 2024
application fee for institutional providers that are initially
enrolling in the Medicare or Medicaid program or the Children's Health
Insurance Program (CHIP); revalidating their Medicare, Medicaid, or
CHIP enrollment; or adding a new Medicare practice location. This fee
is required with any enrollment application submitted on or after
January 1, 2024 and on or before December 31, 2024.
[[Page 76755]]
DATES: The application fee announced in this notice is effective on
January 1, 2024.
FOR FURTHER INFORMATION CONTACT: Frank Whelan, (410) 786-1302.
SUPPLEMENTARY INFORMATION:
I. Background
In the February 2, 2011 Federal Register (76 FR 5862), we published
a final rule with comment period titled ``Medicare, Medicaid, and
Children's Health Insurance Programs; Additional Screening
Requirements, Application Fees, Temporary Enrollment Moratoria, Payment
Suspensions and Compliance Plans for Providers and Suppliers.'' This
rule finalized, among other things, provisions related to the
submission of application fees as part of the Medicare, Medicaid, and
CHIP provider enrollment processes. As provided in section
1866(j)(2)(C)(i) of the Social Security Act (the Act) and in 42 CFR
424.514, ``institutional providers'' that are initially enrolling in
the Medicare or Medicaid programs or CHIP, revalidating their
enrollment, or adding a new Medicare practice location are required to
submit a fee with their enrollment application. An ``institutional
provider'' for purposes of Medicare is defined at Sec. 424.502 as
``any provider or supplier that submits a paper Medicare enrollment
application using the CMS-855A, CMS-855B (not including physician and
non-physician practitioner organizations), CMS-855S, or associated
internet-based PECOS enrollment application.'' As we explained in the
February 2, 2011 final rule (76 FR 5914), in addition to the providers
and suppliers subject to the application fee under Medicare, Medicaid-
only and CHIP-only institutional providers would include nursing
facilities, intermediate care facilities for persons with intellectual
disabilities (ICF/IID), and psychiatric residential treatment
facilities; they may also include other institutional provider types
designated by a state in accordance with their approved state plan.
As indicated in Sec. 424.514 and Sec. 455.460, the application
fee is not required for either of the following:
A Medicare physician or non-physician practitioner
submitting a CMS-855I.
A prospective or revalidating Medicaid or CHIP provider--
++ Who is an individual physician or non-physician practitioner; or
++ That is enrolled as an institutional provider in Title XVIII of
the Act or another state's Title XIX or XXI plan and has paid the
application fee to a Medicare contractor or another state.
II. Provisions of the Notice
Section 1866(j)(2)(C)(i)(I) of the Act established a $500
application fee for institutional providers in CY 2010. Consistent with
section 1866(j)(2)(C)(i)(II) of the Act, Sec. 424.514(d)(2) states
that for CY 2011 and subsequent years, the preceding year's fee will be
adjusted by the percentage change in the consumer price index (CPI) for
all urban consumers (all items; United States city average, CPI-U) for
the 12-month period ending on June 30 of the previous year.
Consequently, each year since 2011 we have published in the Federal
Register an announcement of the application fee amount for the
forthcoming CY based on this formula. Most recently, in the December 5,
2022 Federal Register (87 FR 74422), we published a notice announcing a
fee amount for the period of January 1, 2023 through December 31, 2023
of $688.00. The $688.00 fee amount for CY 2023 will be used to
calculate the fee amount for 2024 as specified in Sec. 424.514(d)(2).
According to Bureau of Labor Statistics (BLS) data, the CPI-U
increase for the period of July 1, 2022 through June 30, 2023 was 3.0
percent. As required by Sec. 424.514(d)(2), the preceding year's fee
of $688 will be adjusted by 3.0 percent. This results in a CY 2024
application fee amount of $708.64 ($688 x 1.03). As we must round this
to the nearest whole dollar amount, the resultant application fee
amount for CY 2024 is $709.00.
III. Collection of Information Requirements
This document does not impose information collection requirements
(that is, reporting, recordkeeping, or third-party disclosure
requirements). Accordingly, there is no need for review by the Office
of Management and Budget under the authority of the Paperwork Reduction
Act of 1995. However, it does reference previously approved information
collections. The CMS-855A, CMS-855B, CMS-855I, and CMS-855S
applications are approved under, respectively, OMB control numbers
0938-0685, 0938-1377, 0938-1355, and 0938-1056.
IV. Regulatory Impact Statement
A. Background and Review Requirements
We have examined the impact of this notice as required by Executive
Order 12866 on Regulatory Planning and Review (September 30, 1993),
Executive Order 13563 on Improving Regulation and Regulatory Review
(January 18, 2011), the Regulatory Flexibility Act (RFA) (September 19,
1980, Pub. L. 96-354), section 1102(b) of the Act, section 202 of the
Unfunded Mandates Reform Act of 1995 (March 22, 1995; Pub. L. 104-4),
and Executive Order 13132 on Federalism (August 4, 1999).
Executive Orders 12866 and 13563 direct agencies to assess all
costs and benefits of available regulatory alternatives and, if
regulation is necessary, to select regulatory approaches that maximize
net benefits (including potential economic, environmental, public
health and safety effects, distributive impacts, and equity). The
Executive Order 14094 entitled ``Modernizing Regulatory Review''
(hereinafter, the Modernizing E.O.) amends section 3(f)(1) of Executive
Order 12866 (Regulatory Planning and Review). The amended section 3(f)
of Executive Order 12866 defines a ``significant regulatory action'' as
an action that is likely to result in a rule: (1) having an annual
effect on the economy of $200 million or more in any 1 year (adjusted
every 3 years by the Administrator of OIRA for changes in gross
domestic product), or adversely affect in a material way the economy, a
sector of the economy, productivity, competition, jobs, the
environment, public health or safety, or State, local, territorial, or
tribal governments or communities; (2) creating a serious inconsistency
or otherwise interfering with an action taken or planned by another
agency; (3) materially altering the budgetary impacts of entitlement
grants, user fees, or loan programs or the rights and obligations of
recipients thereof; or (4) raise legal or policy issues for which
centralized review would meaningfully further the President's
priorities or the principles set forth in this Executive order, as
specifically authorized in a timely manner by the Administrator of OIRA
in each case.
A regulatory impact analysis (RIA) must be prepared for major rules
with significant regulatory action/s and/or with significant effects as
per section 3(f)(1) ($200 million or more in any 1 year). Accordingly,
we have prepared a Regulatory Impact Analysis that to the best of our
ability presents the costs and benefits of the rulemaking. Based on our
estimates, OMB's Office of Information and Regulatory Affairs has
determined that this notice is ``not significant'' and ``not major''.
B. Costs
The costs associated with this notice involve the increase in the
application fee amount that certain providers and suppliers must pay in
CY 2024. The CY 2024 cost estimates are as follows:
[[Page 76756]]
1. Medicare
Based on CMS data, we estimate that in CY 2024 approximately--
14,232 newly enrolling institutional providers will be
subject to and pay an application fee; and
36,142 revalidating institutional providers will be
subject to and pay an application fee.
Using a figure of 50,374 (14,232 newly enrolling + 36,142
revalidating) institutional providers, we estimate an increase in the
cost of the Medicare application fee requirement in CY 2024 of
$1,057,854 (or 50,374 x $21 (or $709 minus $688)) from our CY 2023
projections.
2. Medicaid and CHIP
Based on CMS and state statistics, we estimate that approximately
30,000 (9,000 newly enrolling + 21,000 revalidating) Medicaid and CHIP
institutional providers will be subject to an application fee in CY
2024. Using this figure, we project an increase in the cost of the
Medicaid and CHIP application fee requirement in CY 2024 of $630,000
(or 30,000 x $21 (or $709 minus $688)) from our CY 2023 projections.
3. Total
Based on the foregoing, we estimate the total increase in the cost
of the application fee requirement for Medicare, Medicaid, and CHIP
providers and suppliers in CY 2024 to be $1,687,854 ($1,057,854 +
$630,000) from our CY 2023 projections.
We do not anticipate any negative impact on equity from the
increase in the application fee amount, which we calculated in
accordance with the requirements specified in statute and regulation.
Prior application fee increases have had no such discernable effect,
and we reiterate that the fee requirement does not apply to individual
physicians and non-physician practitioners completing the CMS-855I, who
represent the overwhelming preponderance of the more than 2 million
Medicare-enrolled providers and suppliers.
The RFA requires agencies to analyze options for regulatory relief
of small businesses. For purposes of the RFA, small entities include
small businesses, nonprofit organizations, and small governmental
jurisdictions. Most hospitals and most other providers and suppliers
are small entities, either by nonprofit status or by having revenues of
less than $9 million to $47 million in any 1 year. Individuals and
states are not included in the definition of a small entity. As we
stated in the RIA for the February 2, 2011 final rule (76 FR 5952), we
do not believe that the application fee will have a significant impact
on small entities.
In addition, section 1102(b) of the Act requires us to prepare a
regulatory impact analysis if a rule may have a significant impact on
the operations of a substantial number of small rural hospitals. This
analysis must conform to the provisions of section 604 of the RFA. For
purposes of section 1102(b) of the Act, we define a small rural
hospital as a hospital that is located outside of a Metropolitan
Statistical Area for Medicare payment regulations and has fewer than
100 beds. We are not preparing an analysis for section 1102(b) of the
Act because we have determined, and the Secretary certifies, that this
notice would not have a significant impact on the operations of a
substantial number of small rural hospitals.
Section 202 of the Unfunded Mandates Reform Act of 1995 (UMRA) also
requires that agencies assess anticipated costs and benefits before
issuing any rule whose mandates require spending in any 1 year of $100
million in 1995 dollars, updated annually for inflation. In 2023, that
threshold was approximately $198million. The Agency has determined that
there will be minimal impact from the costs of this notice, as the
threshold is not met under the UMRA.
Executive Order 13132 establishes certain requirements that an
agency must meet when it promulgates a proposed rule (and subsequent
final rule) that imposes substantial direct requirement costs on state
and local governments, preempts state law, or otherwise has federalism
implications. Since this notice does not impose substantial direct
costs on state or local governments, the requirements of Executive
Order 13132 are not applicable.
In accordance with the provisions of Executive Order 12866, this
notice was reviewed by the Office of Management and Budget.
The Administrator of the Centers for Medicare & Medicaid Services
(CMS), Chiquita Brooks-LaSure, having reviewed and approved this
document, authorizes Chyana Woodyard, who is the Federal Register
Liaison, to electronically sign this document for purposes of
publication in the Federal Register.
Chyana Woodyard,
Federal Register Liaison, Centers for Medicare & Medicaid Services.
[FR Doc. 2023-24607 Filed 11-6-23; 8:45 am]
BILLING CODE 4120-01-P